Abraxane – Paclitaxel Albumin-bound

What is Paclitaxel Albumin-bound?

Paclitaxel Albumin-bound (also referred to as protein bound) is also known as Abraxane. It is commonly confused with “conventional paclitaxel” or just “paclitaxel.” However, paclitaxel albumin-bound is formulated differently and not used for treating as many cancer types as “conventional paclitaxel.” This medication is in a category of chemotherapy drugs known as antimicrotubulars; it inhibits cell growth by focusing on the microtubules found in cells. It is a chemotherapy used to treat metastatic breast cancer, non-small cell lung cancer and metastatic pancreatic cancer.

How it is administered:

Paclitaxel albumin-bound is given intravenously over 30 minutes. It may be given in combination with other medications. For metastatic pancreatic cancer, it is given in combination with gemcitabine (Gemzar). For non-small cell lung cancer, this medications is given in combination with carboplatin (Paraplatin).

What to expect:

Typically, paclitaxel albumin-bound is not very nauseating but a decrease in appetite is a side-effect of this medication. It can cause anemia and reduce the body’s ability to fight infections. Additionally, tingling and/or loss of sensations in the fingers and toes can occur as well. It is important to communicate with your provider any and all changes during treatment.